Cheplapharm Arzneimittel, founded in 1998 and headquartered in Greifswald, Germany, is a leading pharmaceutical company focused on the development and distribution of generic and specialty drugs. The company aims to improve access to essential medications across multiple therapeutic areas, including cardiology, gynecology, and endocrinology. Cheplapharm's robust portfolio comprises both established compounds and innovative therapies, catering to diverse patient needs while promoting sustainable healthcare solutions.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| CHEPDE 3.50% 2027-02-11 EURCheplapharm Arzneimittel | Germany | 2027-02-11 | 3.500 | 3.29 |
| CHEPDE 3.50% 2027-02-11 EURCheplapharm Arzneimittel | Germany | 2027-02-11 | 3.500 | 3.29 |
| CHEPDE 4.38% 2028-01-15 EURCheplapharm Arzneimittel | Germany | 2028-01-15 | 4.375 | -0.19 |
| CHEPDE 4.38% 2028-01-15 EURCheplapharm Arzneimittel | Germany | 2028-01-15 | 4.375 | -0.19 |
| CHEPDE 5.50% 2028-01-15 USDCheplapharm Arzneimittel | Germany | 2028-01-15 | 5.500 | 5.52 |
| CHEPDE 5.50% 2028-01-15 USDCheplapharm Arzneimittel | Germany | 2028-01-15 | 5.500 | 5.52 |
| CHEPDE 7.50% 2030-05-15 EURCheplapharm Arzneimittel | Germany | 2030-05-15 | 7.500 | 6.36 |
| CHEPDE 7.50% 2030-05-15 EURCheplapharm Arzneimittel | Germany | 2030-05-15 | 7.500 | 6.36 |
| CHEPDE 8.75% 2030-05-15 EURCheplapharm Arzneimittel | Germany | 2030-05-15 | 8.752 | 6.69 |
| CHEPDE 8.75% 2030-05-15 EURCheplapharm Arzneimittel | Germany | 2030-05-15 | 8.752 | 6.68 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Cheplapharm has actively participated in the bond market since 2018, with notable issuances that support its growth and expansion strategies. The company's recent €150 million bond issuance was aimed at refinancing existing debt and funding new product developments, reflecting its commitment to maintaining a strong financial position. Currently, Cheplapharm's bonds offer competitive yields compared to industry peers, with features such as early redemption options that appeal to investors seeking flexibility. Notably, the company's stability and growth prospects have led to positive ratings by credit agencies, drawing increasing interest from retail investors.